Drug Trial Radar · NCT01578200
Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study
Last checked: Nov 20, 2026Latest source record: Nov 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,309
Actual
Start
Dec 24, 2011
Primary completion
Mar 25, 2019
Study completion Mar 25, 2019
Sponsor
- Lead sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Showa University School of Medicine
- First posted
- Apr 16, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate decrease in cardiovascular mortality and morbidity in Japanese hemodialysis patients treated with Lanthanum carbonate compared with those with Calcium carbonate.
Conditions
- Hemodialysis
- Hyperphosphatemia
Interventions
Lanthanum CarbonateDrug
Calcium CarbonateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cardiovascular event free survival time.Time frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Showa University
Shinagawa, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.